Bayer's Pipeline Wins Give Analysts Fresh Ammunition, but the Cash Register Has Yet to Ring
Published on 11/11/2026 at 02:51 | Editorial boerse-global.de
Two regulatory green lights and a broker upgrade have handed Bayer a rare stretch of good news. Whether it translates into a sturdier investment case hinges on a less glamorous question: can the German group turn medical breakthroughs into cash?
Deutsche Bank Research raised its price target on Bayer to EUR 65 from EUR 60, reaffirming its buy rating. The more consequential signal, though, sits in the earnings revisions beneath that headline number. Analyst Virginie Boucher-Ferte lifted her forecast for adjusted EBITDA in fiscal 2026 by roughly 3% to EUR 10,060 million, with the pharmaceuticals division doing the heavy lifting. Crop Science expectations, by contrast, were trimmed slightly.
That split tells its own story. The upgrade is a targeted re-rating of Bayer's earnings power rather than a blanket vote of confidence, and it puts the onus squarely on the drug business to keep delivering. Boucher-Ferte also raised her EBITDA and earnings-per-share estimates for 2027 and 2028 by about 3% each, extending the more bullish view well beyond the current year.
Two approvals, one broader platform
The pharma optimism has fresh regulatory foundations. On November 4, Bayer reported China's approval of Sevabertinib as a first-line treatment for adults with advanced HER2-mutant non-small cell lung cancer. That followed the U.S. clearance of Asundexian, marketed as Sunharbo, for secondary prevention after a recent non-cardioembolic ischemic stroke or high-risk TIA, given alongside antiplatelet therapy. Bayer bills the compound as the first factor XIa inhibitor approved anywhere in the world.
The clinical evidence behind Asundexian is what gives the commercial hope its footing. According to the FDA, the drug cut the risk of ischemic stroke by 26% versus placebo over a median treatment duration of 14.2 months. Reuters has reported that Asundexian is meant to help offset revenue declines for Xarelto, Bayer's older anticoagulant — meaning the company needs growth that specifically plugs a hole elsewhere.
Should investors sell immediately? Or is it worth buying Bayer?
Not everyone is moved. Jefferies reiterated a hold rating with a EUR 48.50 target, with analyst Michael Leuchten calling the U.S. approval an expected development. That stance is a useful reminder that the regulatory win was already priced in, and that further enthusiasm must be earned through execution.
The existing drugs are already doing the work
Hard numbers from the third quarter of 2026 show where the momentum actually resides. Pharma EBITDA climbed 23.6%, lifting the division's margin to 27.6%. Nubeqa grew sales by 58.3% in currency-adjusted terms to roughly EUR 1 billion, while Kerendia posted a 64.9% revenue increase.
That dynamism matters as much as the pipeline promises. If Bayer's established growth drivers keep converting into reliably higher profitability, the raised earnings assumptions look far less speculative. Group revenue for the quarter came in at EUR 10.053 billion, with EBITDA before special items at EUR 1.615 billion — figures that arrived alongside an upgrade to full-year guidance covering the pharmaceuticals margin, group EBITDA before special items and free cash flow.
The balance sheet keeps the score
The financial counter-check is where the bull case loses some shine. Bayer booked a net loss of EUR 672 million in the third quarter of 2026 and generated negative free cash flow of EUR 293 million. Net financial debt stood at EUR 31.1 billion at the end of September 2026, a figure that already reflects EUR 3 billion in proceeds from the Apollo transaction.
Debt reduction is real progress, but it will only count for so much if the operating business cannot fund itself. Higher adjusted earnings strengthen Bayer chiefly when they translate into tangible financial relief; a healthier cash inflow would lend the operational advances far more weight and lay the groundwork for further deleveraging.
Weighing it all together, the Deutsche Bank upgrade rests on defensible operational ground — provided the pharmaceutical strength endures. The next convincing milestone, however, will be financial rather than regulatory: new medicines that genuinely offset the decline of older products, and a cash flow that finally turns the corner.
Ad
Bayer Stock: New Analysis - 11 November
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
